- Samsung Biologics has been recognised for the fourth consecutive year in the Dow Jones Sustainability World Index (DJSI) for its commitment to sustainability.
- The company continues its focus on achieving net-zero emissions and supporting the biopharma sector’s environmental goals.
Samsung Biologics, a contract development and manufacturing services provider (CDMO), has been recognised for the fourth consecutive year in the prestigious Dow Jones Sustainability World Index (DJSI). This accolade highlights the company’s ongoing commitment to integrating sustainable business practices throughout its operations. The index, which evaluates over 2,500 publicly traded companies worldwide, noted Samsung Biologics for its strong environmental initiatives, particularly in carbon reduction and efforts towards net-zero emissions.
John Rim, President and CEO of Samsung Biologics expressed pride in the company’s achievements, stating, “This achievement demonstrates our commitment to driving sustainability across our operations and the broader biopharma value chain.” The company remains focused on supporting both its own sustainability goals and those of its clients, contributing to a healthier world through its environmental, social, and governance (ESG) efforts.
Beyond its efforts within the company, Samsung Biologics plays a key role in the industry’s transition to sustainable practices. The company is a champion of the Supply Chains Working Group within the Sustainable Markets Initiative (SMI), working with global suppliers to decarbonize and build resilient value chains. In addition, Samsung Biologics has accelerated its transition to renewable energy with the signing of a Power Purchase Agreement and a Renewable Energy Certificate.
As part of its broader sustainability strategy, Samsung Biologics has also completed Product Carbon Footprint measurements, assisting its clients in reaching their net-zero goals. The company’s ongoing commitment to sustainability has been further recognised through its participation in the Pharmaceutical Supply Chain Initiative and its receipt of an EcoVadis platinum sustainability rating.
Overview of outsourcing trends 
